Telomir Pharmaceuticals Commences Two Milestones For Telomir-1
Portfolio Pulse from Benzinga Newsdesk
Telomir Pharmaceuticals has commenced a study to evaluate the safety of Telomir-1 when administered orally to geriatric Beagle dogs for 63 consecutive days. The study began on May 28th, and initial dosing was well-tolerated by all animals. The data will explore the potential for treating age-related conditions.
May 30, 2024 | 12:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Telomir Pharmaceuticals has initiated a study to evaluate the safety of Telomir-1 in geriatric Beagle dogs. The study's initial dosing was well-tolerated, which is a positive indicator for the potential treatment of age-related conditions.
The commencement of the study and the positive initial results are likely to boost investor confidence in Telomir Pharmaceuticals. The potential for Telomir-1 to treat age-related conditions could lead to future revenue growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100